Many elderly patients with metastatic renal cell carcinoma benefit from targeted therapies

PHILADELPHIA–Many elderly patients with metastatic renal cell carcinoma (RCC)–who are often underrepresented in clinical trials to treat the kidney cancer–are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open. Analyzing 13 years of data on Medicare patients, the study…